




PHARMACEUTICAL 2018

Evofem Biosciences Inc.
Rank 304 of 342





PHARMACEUTICAL 2018

Evofem Biosciences Inc.
Rank 304 of 342

The relative strengths and weaknesses of Evofem Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evofem Biosciences Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Evofem Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 236% points.

The company's Economic Capital Ratio, given in the ranking table, is -193%, being 239% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	4,025
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,412
Liabilities, Non-Current	0
Other Assets	93
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	51
Other Revenues	0
Property and Equipment	0
Research and Development	3,946
Selling, General and Administrative Expense	6,099

Output Variable	Value in 1000 USD
Assets	4,119
Liabilities	1,412
Expenses	10,045
Revenues	0
Stockholders Equity	2,707
Net Income	-9,993
Comprehensive Net Income	-9,993
Economic Capital Ratio	-193%